Effectiveness of the Dual Serotonin Norepinephrine Reuptake Inhibitor Venlafaxine in Depressed Patients

Completed

• Conditions: Major Depression; Mental and Behavioural Disorders; Depression

• Registration Number: ISRCTN87057460
• Lead Sponsor: Wyeth Pharmaceuticals (Canada)

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2005-09-29
• Last Update Posted: 13 January 2015

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 40

Inclusion Criteria

1. Male or female patients between 18 and 65 years of age
2. Diagnosis of major depression according to the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV) (American Psychiatry Association, 1994) using the Structured Clinical Interview for Depression (SCID) (Spitzer 1992)
3. Initial global score 18 on the 17-item Hamilton depression rating scale
4. Written informed consent signed by the patient

Exclusion Criteria

1. Evidence of significant physical illness contraindicating the use of Venlafaxine, Paroxetine or Atomoxetine found on physical or in the laboratory data obtained during the first week of the study
2. Evidence of suicidality or severity of depression precluding safe participation in the study
3. Mental retardation (IQ lower than 80) rendering the response to investigators unreliable
4. Pregnancy, or absence of adequate contraceptive method in women with childbearing potential
5. Concurrent use of psychotropic medication such as antipsychotics, mood stabilizers or regular use of high doses of benzodiazepines
6. Lack of response or intolerance to optimal doses of Paroxetine, Venlafaxine or Atomoxetine
7. Participation in another clinical trial within 30 days of entry into the current study

Study & Design

• Study Type: Interventional
• Study Design: Not specified